Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States

Gao, Xu; Lv, Fan; He, Xinyuan; Ya, Zhao; Liu, Yi; Zu, Jian; Henry, Linda; Wang, Jinhai; Yeo, Yee Hui; Ji, Fanpu; Nguyen, Mindie H.

doi:10.1016/j.jhep.2022.07.028

Cited by 61 publications

(47 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We congratulate Gao et al for their recent study showing increasing liver-related mortality during the COVID-19 pandemic in the United States. 1 We note that deaths for alcohol-associated liver disease (ALD) increased more than other etiologies, in parallel with other studies that have shown increases in liver transplantation (LT) for ALD during the 1 st year of COVID-19, hypothesized to be related to increased alcohol use from pandemic-related stressors. [2] , [3] , [4] , [5] The public pandemic response changed significantly in the second year, with liftings of lock-down policies and return of pre-pandemic activities.…”

Section: Disclosuressupporting

confidence: 70%

Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults

Lee

Dodge

Terrault

2023

Journal of Hepatology

View full text Add to dashboard Cite

Section: Disclosuressupporting

confidence: 70%

Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults

Lee

Dodge

Terrault

2023

Journal of Hepatology

View full text Add to dashboard Cite

“…14 Another recent study showed an increase in both COVID-19-related and non-COVID-19-related mortality of patients with ALD. 15 Enhanced mental health service and alcohol treatment programs are urgently needed. Meanwhile, the delayed surge in NAFLD and ALD call for additional provider and patient education to maintain best practice monitoring and treatment despite the pandemic.…”

Section: Discussionmentioning

confidence: 99%

Trends of Cirrhosis-related Mortality in the USA during the COVID-19 Pandemic

Yeo¹,

He²,

Lv³

et al. 2022

J Clin Transl Hepatol

Self Cite

View full text Add to dashboard Cite

Immunocompromised status and interrupted routine care may render patients with cirrhosis vulnerable to the coronavirus disease 2019 (COVID-19) pandemic. A nationwide dataset that includes more than 99% of the decedents in the U.S. between April 2012 and September 2021 was used. Projected age-standardized mortality during the pandemic were estimated according to prepandemic mortality rates, stratified by season. Excess deaths were determined by estimating the difference between observed and projected mortality rates. A temporal trend analysis of observed mortality rates was also performed in 0.83 million decedents with cirrhosis between April 2012 and September 2021 was included. Following an increasing trend of cirrhosis-related mortality before the pandemic, with a semiannual percentage change (SAPC) of 0.54% [95% confidence interval (CI): (0.0-1.0%), p=0.036], a precipitous increase with seasonal variation occurred during the pandemic (SAPC 5.35, 95% CI: 1.9-8.9, p=0.005). Significantly increased mortality rates were observed in those with alcohol-associated liver disease (ALD), with a SAPC of 8.44 (95% CI: 4.3-12.8, p=0.001) during the pandemic. Allcause mortality of nonalcoholic fatty liver disease rose steadily across the entire study period with a SAPC of 6.79 (95% CI: 6.3-7.3, p<0.001). The decreasing trend of HCV-related mortality was reversed during the pandemic, while there was no significant change in HBV-related deaths. While there was significant increase in COVID-19-related deaths, more than 55% of the excess deaths were the indirect impact of the pandemic. We observed an alarming increase in cirrhosisrelated deaths during the pandemic especially for ALD, with evidence in both direct and indirect impact. Our findings have implications on formulating policies for patients with cirrhosis.

show abstract

“…At the same time, the current COVID-19 pandemic has caused severe disruption in access to healthcare and rising cost of living that may worsen the current obesity and metabolic disease epidemics, which can contribute to even higher NAFLD prevalence. In fact, population-based data from the United States have shown increased mortality during the COVID-19 pandemic as compared to the predicted level based on past trends for several chronic liver disease, including NAFLD, and especially in ethnic minorities [ 39 , 40 ]. However, the information provided in our analysis provides a worst-case scenario which may help policy makers in developing policies to raise awareness of NAFLD, while simultaneously providing direction and funding for reversing the upward trajectory for both obesity and type 2 diabetes mellitus.…”

Section: Discussionmentioning

confidence: 99%

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Due to increases in obesity and type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is increasing. Current forecast models may not include non-obese NAFLD. We used a Bayesian approach forecasting the prevalence of NAFLD through 2040.Methods: Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were conducted for age, gender, presence of metabolic syndrome, region, and smoking. Sensitivity analysis was conducted for clinical setting and study quality.Results: Forecasted 2040 prevalence rate was 55.7%, a 3-times increase since 1990 and 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years old, the 2040 prevalence rates were not different (56.7% vs 61.5%, P=0.52).There was a significant difference in 2040 prevalence by sex (males-60% vs.50%, P+) but trend is stepper for females (2.5% vs 1.5%, P=0.025). No difference in trends overtime by region (P=0.48). The rate of increase was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and for smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or the quality of the studies (P=0.85) Conclusion: By 2040, over half the adult population is forecasted to have NAFLD. The largest increases occur in women, smokers and those without metabolic syndrome. Intensification of efforts raising awareness and determining long term solutions addressing driving factors of NAFLD are needed.

show abstract

Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States

Cited by 61 publications

References 37 publications

Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults

Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults

Trends of Cirrhosis-related Mortality in the USA during the COVID-19 Pandemic

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Contact Info

Product

Resources

About